Literature DB >> 9683260

Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function.

R P Dong1, K Tachibana, M Hegen, S Scharpé, D Cho, S F Schlossman, C Morimoto.   

Abstract

To clarify the different anti-CD26 mAbs corresponding different functions of CD26, the correlation of the epitopes defined by anti-CD26 mAbs and the functions of CD26 have been studied. Using truncated, human-rat CD26 swap mutants and cross-blocking studies, 13 anti-CD26 mAbs were divided into 5 separate groups. These 5 epitopes were localized between the 1-247th, 248-358th, 359-449th (closer to the 359th amino acid), 450-577th and 359 653th amino acid regions. MAbs against two of these five epitopes, the 248-358th and 359-449th amino acid regions, were associated with inducing modulation of CD26 and T-cell costimulation through the CD3 pathway. Furthermore, mAbs against one of these epitopes, the 359-449th amino acid region, appeared to encompass the ADA binding domain. Analysing the avidity of each mAb to the CD26 molecule using DPPIV enzymatic activity as an indicator, we found that the function of CD26 had little correlation with the avidity of anti-CD26 mAbs, suggesting that distinct epitopes defined by anti-CD26 mAbs appeared to be associated with different functions of CD26. These results will be very useful in the further definition of the functional domains of CD26.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683260     DOI: 10.1016/s0161-5890(98)00015-7

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  12 in total

1.  CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.

Authors:  T Ishii; K Ohnuma; A Murakami; N Takasawa; S Kobayashi; N H Dang; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

2.  Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum.

Authors:  Kei Ohnuma; Tatsuhiko Saito; Ryou Hatano; Osamu Hosono; Satoshi Iwata; Nam H Dang; Hiroki Ninomiya; Chikao Morimoto
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

3.  Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation.

Authors:  H Ikushima; Y Munakata; T Ishii; S Iwata; M Terashima; H Tanaka; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  G1/S cell cycle arrest provoked in human T cells by antibody to CD26.

Authors:  Kei Ohnuma; Tomonori Ishii; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Masahiko Uchiyama; Hirotoshi Tanaka; Tadanori Yamochi; Nam H Dang; Chikao Morimoto
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

5.  Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.

Authors:  Kei Ohnuma; Bart L Haagmans; Ryo Hatano; V Stalin Raj; Huihui Mou; Satoshi Iwata; Nam H Dang; Berend Jan Bosch; Chikao Morimoto
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

6.  Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.

Authors:  Ryo Hatano; Taketo Yamada; Shuji Matsuoka; Satoshi Iwata; Hiroto Yamazaki; Eriko Komiya; Toshihiro Okamoto; Nam H Dang; Kei Ohnuma; Chikao Morimoto
Journal:  Diagn Pathol       Date:  2014-02-06       Impact factor: 2.644

7.  First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Authors:  Eric Angevin; Nicolas Isambert; Véronique Trillet-Lenoir; Benoit You; Jérôme Alexandre; Gérard Zalcman; Philippe Vielh; Françoise Farace; Fanny Valleix; Thomas Podoll; Yu Kuramochi; Itaru Miyashita; Osamu Hosono; Nam H Dang; Kei Ohnuma; Taketo Yamada; Yutaro Kaneko; Chikao Morimoto
Journal:  Br J Cancer       Date:  2017-03-14       Impact factor: 7.640

8.  Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.

Authors:  Ryo Hatano; Taketo Yamada; Hiroko Madokoro; Haruna Otsuka; Eriko Komiya; Takumi Itoh; Yuka Narita; Satoshi Iwata; Hiroto Yamazaki; Shuji Matsuoka; Nam H Dang; Kei Ohnuma; Chikao Morimoto
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

9.  CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.

Authors:  Hiroko Nishida; Mutsumi Hayashi; Chikao Morimoto; Michiie Sakamoto; Taketo Yamada
Journal:  Blood Cancer J       Date:  2018-10-22       Impact factor: 11.037

Review 10.  Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.

Authors:  Hiroko Nishida; Taketo Yamada
Journal:  J Oncol       Date:  2019-11-03       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.